Placebo-Controlled, Dose-Escalation Study to Assess Safety, Tolerability, PK and PD of a GalNAc3 Conjugated Antisense Oligonucleotide Targeting ApoC-III, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides

Trial Profile

Placebo-Controlled, Dose-Escalation Study to Assess Safety, Tolerability, PK and PD of a GalNAc3 Conjugated Antisense Oligonucleotide Targeting ApoC-III, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs IONIS APOCIII LRx (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2017 According to an Akcea Therapeutics media release, company announced positive results from this trial.
    • 31 Oct 2017 Results presented in an Akcea Therapeutics Media Release.
    • 08 Aug 2017 According to an Ionis Pharmaceuticals media release, results from this trial are expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top